The effect analysis and prevention effects of nucleic acid testing combined with enzyme linked immunosorbent assay on blood-borne diseases.

To investigate the effect analysis and preventive effects of nucleic acid testing combined with enzyme-linked immunosorbent assay (ELISA) on blood-borne diseases. This study included 72335 blood samples that were collected in our hospital from March 2019 to March 2020. All the samples were tested for anti HIV (AIDS antibody), anti HCV (hepatitis C antibody), HBsAg (hepatitis B surface antigen) and anti TP (syphilis antibody) in blood respectively with two manufacturers' reagents. The results of anti HIV, anti HCV, HBsAg and anti TP of all samples were analyzed, and blood samples with 0.7< sample test value / critical value (s / CO) < 3.0 were tested by ELISA and negative blood samples were tested by ELISA and nucleic acid testing. Then we analyzed the results of nucleic acid testing. 610 blood samples failed to pass the test of anti HIV, anti HCV, HBsAg and anti TP ELISA, accounting for 0.84% of the total numbers, including 100 blood samples with 1.0 <s/Co <3.0, 172 blood samples with S/CO > 3.0, 338 blood samples with 0.7< s/CO <1.0 and 71725 blood samples were qualified. We used nucleic acid testing to test 71725 qualified samples tested by ELISA and then there were 50 samples with positive HBV-DNA , accounting for 0.07% (50 / 71725), no one with positive HIV-RNA and positive HCV-RNA, accounting for 0.00% (0/71725). The positive rate of blood samples with HBsAg 0.7 <s/CO <1.0 tested by ELISA and nucleic acid testing was 7 (5.83%), which was significantly lower than 9 (20.93%) of blood samples with HBsAg 1.0< s / Co < 3.0 tested by ELISA (X2= 8.15, P<0.01). In the clinical test of blood-borne disease, the joint test of nucleic acid testing and enzyme-linked immunosorbent assay reduces the occurrence of virus omission, and plays a positive role in preventing from spreading diseases through blood transfusion.